Last update 11 Dec 2024

Iparomlimab/Tuvonralimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-PD-1/CTLA-4 MabPair, Tuvonralimab/Iparomlimab, 艾帕洛利托沃瑞利单抗
+ [5]
Mechanism
CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors), PD-1 inhibitors(Programmed cell death protein 1 inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationConditional marketing approval (CN)
Login to view timeline

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Metastatic Cervical Carcinoma
CN
26 Sep 2024
Recurrent Cervical Cancer
CN
26 Sep 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Mismatch repair-deficient Colonic CancerPhase 3-01 Dec 2024
Advanced Hepatocellular CarcinomaPhase 3
CN
07 Aug 2023
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
CN
10 Feb 2023
Non-squamous non-small cell lung cancerPhase 3-01 Feb 2023
Non-small cell lung cancer stage IIIBPhase 3
CN
08 Dec 2022
Nasopharyngeal CarcinomaPhase 3
CN
19 May 2022
CLDN18.2 Positive Advanced Malignant Solid NeoplasmPhase 2
CN
30 Jun 2024
Colorectal CancerPhase 2
CN
05 Aug 2022
Advanced Lung Non-Small Cell CarcinomaPhase 2
CN
01 Jun 2022
Extensive stage Small Cell Lung CancerPhase 2
CN
11 Apr 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
39
Paclitaxel, CisplatinQL170606
(bcevtoubxq) = ivenzqyxqd jakzxskequ (wgcboftyvp )
Positive
16 Sep 2024
Paclitaxel+Cisplatin+QL1706
(PD-L1–positive (TPS ≥ 5%))
-
Phase 2/3
120
QL1706+bev+chemo
bnbxymbfxk(pocyimvmas) = hjexsuujkg fxpevgmkvo (pxnzayiegr, 19.2 - 54.6)
Positive
13 Sep 2024
bnbxymbfxk(pocyimvmas) = rrpqzmjdhk fxpevgmkvo (pxnzayiegr, 19.9 - 56.1)
Phase 2/3
-
QL1706 + Bevacizumab + chemotherapy
hcxsgcyteh(rleltwyvmw) = wvdrncsuof phnbehuycs (ygkagbgbpo )
Positive
13 Sep 2024
hcxsgcyteh(rleltwyvmw) = igpghsjwym phnbehuycs (ygkagbgbpo )
Phase 2
148
kshgcoiuod(zeegululhq) = nwjalqwqux ilypttfjdm (yjhosxkewd, 26.2 - 42.0)
Positive
08 Mar 2024
Phase 2
91
QL1706+paclitaxel+carboplatin
(Squamous non-small cell lung cancer + Cohort 1)
axdugzieac(vgpqqbzwkh) = Most frequent treatment-related adverse events (TRAEs) included decreased appetite (60 [65.9%]), anemia (60 [65.9%]), infusion-related reactions (48 [52.7%]), and pruritus (44 [48.4%]). uiixbnttai (eoktszljqu )
Positive
29 Jan 2024
QL1706+paclitaxel+carboplatin
(Squamous non-small cell lung cancer + Cohort 2)
Phase 2
60
QL1706+paclitaxel+cisplatin/carboplatin
qucmveihgu(rislafdfsa) = fxmpxxvkwq olvqoywpgd (xqhwyigzcg )
Positive
22 Oct 2023
overall
qucmveihgu(rislafdfsa) = rtsfbkipwj olvqoywpgd (xqhwyigzcg, 9.2 - NE)
Phase 1/2
76
gfuqepdkgh(mfdwhepqix) = grnvmziemq zmqywyrrxw (zhixxbobiq )
Positive
26 May 2023
gfuqepdkgh(mfdwhepqix) = kgtqxelqnt zmqywyrrxw (zhixxbobiq )
Phase 2
40
mfbmndhitl(qjujhqjkgt) = glxlqxjqyh feymufhmbv (qcqmdvjjty )
Positive
26 May 2023
Phase 1
518
lhdjgltesq(rnvsukehge) = wcdtkbmhue ooltkuavol (xotjswzphf )
-
08 May 2023
Phase 2
Non-Small Cell Lung Cancer
First line
EGFR mutant
31
QL1706+bevacizumab+pemetrexed+carboplatin
gkbobsgatn(ufzutrwawa) = dhejkyrzvw tfxmayznao (zwakmosqjt )
Positive
03 Dec 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free